CSL Limited (CSLLY)
USD 81.65
(0.89%)
USD 81.65
(0.89%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 38.02 Billion USD | -30.15% |
| 2023 | 36.23 Billion USD | 27.83% |
| 2022 | 28.34 Billion USD | 56.12% |
| 2021 | 18.15 Billion AUD | 17.41% |
| 2020 | 15.46 Billion AUD | 25.58% |
| 2019 | 12.31 Billion AUD | 14.29% |
| 2018 | 10.77 Billion AUD | 18.11% |
| 2017 | 9.12 Billion AUD | 20.63% |
| 2016 | 7.56 Billion AUD | 18.15% |
| 2015 | 6.4 Billion AUD | 1.96% |
| 2014 | 6.27 Billion AUD | 5.06% |
| 2013 | 5.97 Billion AUD | 0.34% |
| 2012 | 5.95 Billion AUD | 9.95% |
| 2011 | 5.41 Billion AUD | 11.6% |
| 2010 | 4.85 Billion AUD | -18.36% |
| 2009 | 5.94 Billion AUD | 32.36% |
| 2008 | 4.49 Billion AUD | 26.1% |
| 2007 | 3.56 Billion AUD | 14.67% |
| 2006 | 3.1 Billion AUD | 5.15% |
| 2005 | 2.95 Billion AUD | 9.03% |
| 2004 | 2.7 Billion AUD | 81.17% |
| 2003 | 1.49 Billion AUD | 14.89% |
| 2002 | 1.3 Billion AUD | 43.97% |
| 2001 | 904.15 Million AUD | 60.0% |
| 2000 | 565.09 Million AUD | 50.75% |
| 1999 | 374.85 Million AUD | 15.29% |
| 1998 | 325.15 Million AUD | -15.58% |
| 1997 | 385.17 Million AUD | 3.04% |
| 1996 | 373.81 Million AUD | 11.44% |
| 1995 | 335.45 Million AUD | 7.29% |
| 1994 | 312.67 Million AUD | 104.26% |
| 1993 | 153.07 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 37.3 Billion USD | 0.0% |
| 2024 Q1 | 58.03 Billion USD | 60.15% |
| 2024 Q4 | 38.02 Billion USD | 0.0% |
| 2024 FY | 38.02 Billion USD | 4.93% |
| 2023 Q2 | 35.44 Billion USD | -36.04% |
| 2023 Q1 | 55.42 Billion USD | 95.52% |
| 2023 FY | 36.23 Billion USD | 27.83% |
| 2023 Q4 | 36.23 Billion USD | -33.15% |
| 2023 Q3 | 54.19 Billion USD | 52.9% |
| 2022 Q4 | 28.34 Billion USD | -25.17% |
| 2022 Q1 | 32.43 Billion USD | 78.64% |
| 2022 Q2 | 23.43 Billion USD | -27.74% |
| 2022 Q3 | 37.87 Billion USD | 61.6% |
| 2022 FY | 28.34 Billion USD | 56.12% |
| 2021 Q1 | 24.71 Billion USD | 9.67% |
| 2021 Q3 | 23.9 Billion USD | 35.11% |
| 2021 Q4 | 18.15 Billion AUD | -24.04% |
| 2021 FY | 18.15 Billion AUD | 17.41% |
| 2021 Q2 | 17.69 Billion USD | -28.41% |
| 2020 FY | 15.46 Billion AUD | 25.58% |
| 2020 Q3 | 25.39 Billion USD | 80.41% |
| 2020 Q4 | 22.53 Billion AUD | -11.26% |
| 2020 Q1 | 20.85 Billion USD | 69.34% |
| 2020 Q2 | 14.07 Billion USD | -32.51% |
| 2019 FY | 12.31 Billion AUD | 14.29% |
| 2019 Q3 | 17.34 Billion USD | 5.94% |
| 2019 Q1 | 15.95 Billion USD | 48.08% |
| 2019 Q2 | 16.37 Billion USD | 2.61% |
| 2019 Q4 | 12.31 Billion AUD | -29.0% |
| 2018 Q3 | 14.02 Billion USD | 5.24% |
| 2018 FY | 10.77 Billion AUD | 18.11% |
| 2018 Q1 | 13.26 Billion USD | 45.36% |
| 2018 Q2 | 13.32 Billion USD | 0.5% |
| 2018 Q4 | 10.77 Billion AUD | -23.18% |
| 2017 Q2 | 11.26 Billion USD | 6.07% |
| 2017 FY | 9.12 Billion AUD | 20.63% |
| 2017 Q4 | 9.12 Billion AUD | -23.6% |
| 2017 Q3 | 11.94 Billion USD | 5.99% |
| 2017 Q1 | 10.62 Billion USD | 40.44% |
| 2016 Q1 | 10.67 Billion USD | 66.72% |
| 2016 FY | 7.56 Billion AUD | 18.15% |
| 2016 Q3 | 9.84 Billion USD | -4.48% |
| 2016 Q2 | 10.3 Billion USD | -3.47% |
| 2016 Q4 | 7.56 Billion AUD | -23.14% |
| 2015 Q3 | 8.39 Billion USD | 5.28% |
| 2015 FY | 6.4 Billion AUD | 1.96% |
| 2015 Q1 | 7.45 Billion USD | 18.79% |
| 2015 Q2 | 7.97 Billion USD | 6.9% |
| 2015 Q4 | 6.4 Billion AUD | -23.73% |
| 2014 Q1 | 6.67 Billion USD | 11.67% |
| 2014 Q3 | 6.77 Billion USD | -2.92% |
| 2014 Q2 | 6.97 Billion USD | 4.51% |
| 2014 FY | 6.27 Billion AUD | 5.06% |
| 2014 Q4 | 6.27 Billion AUD | -7.28% |
| 2013 Q1 | 5.6 Billion USD | -5.94% |
| 2013 Q2 | 5.59 Billion USD | -0.06% |
| 2013 Q3 | 5.73 Billion USD | 2.53% |
| 2013 Q4 | 5.97 Billion AUD | 4.11% |
| 2013 FY | 5.97 Billion AUD | 0.34% |
| 2012 Q4 | 5.95 Billion AUD | 0.0% |
| 2012 FY | 5.95 Billion AUD | 9.95% |
| 2011 Q4 | 5.41 Billion AUD | 0.0% |
| 2011 FY | 5.41 Billion AUD | 11.6% |
| 2010 FY | 4.85 Billion AUD | -18.36% |
| 2010 Q4 | 4.85 Billion AUD | 0.0% |
| 2009 Q4 | 5.94 Billion AUD | 0.0% |
| 2009 FY | 5.94 Billion AUD | 32.36% |
| 2008 Q4 | 4.49 Billion AUD | 0.0% |
| 2008 FY | 4.49 Billion AUD | 26.1% |
| 2007 Q4 | 3.56 Billion AUD | 0.0% |
| 2007 FY | 3.56 Billion AUD | 14.67% |
| 2006 FY | 3.1 Billion AUD | 5.15% |
| 2006 Q4 | 3.1 Billion AUD | 0.0% |
| 2005 FY | 2.95 Billion AUD | 9.03% |
| 2005 Q4 | 2.95 Billion AUD | 0.0% |
| 2004 Q4 | 2.7 Billion AUD | 0.0% |
| 2004 FY | 2.7 Billion AUD | 81.17% |
| 2003 Q4 | 1.49 Billion AUD | 0.0% |
| 2003 FY | 1.49 Billion AUD | 14.89% |
| 2002 FY | 1.3 Billion AUD | 43.97% |
| 2002 Q4 | 1.3 Billion AUD | 0.0% |
| 2001 Q4 | 904.15 Million AUD | 0.0% |
| 2001 FY | 904.15 Million AUD | 60.0% |
| 2000 Q4 | 565.09 Million AUD | 0.0% |
| 2000 FY | 565.09 Million AUD | 50.75% |
| 1999 Q4 | 374.85 Million AUD | 0.0% |
| 1999 FY | 374.85 Million AUD | 15.29% |
| 1998 Q4 | 325.15 Million AUD | 0.0% |
| 1998 FY | 325.15 Million AUD | -15.58% |
| 1997 Q4 | 385.17 Million AUD | 0.0% |
| 1997 FY | 385.17 Million AUD | 3.04% |
| 1996 FY | 373.81 Million AUD | 11.44% |
| 1995 FY | 335.45 Million AUD | 7.29% |
| 1994 FY | 312.67 Million AUD | 104.26% |
| 1993 FY | 153.07 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -1645973925.931% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -1941592.043% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -360161.512% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -6886446.403% |
| Rebus Holdings, Inc. | 5000.00 USD | -760439899.98% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -29100.354% |
| Qrons Inc. | 420.00 USD | -9052857042.619% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -4933695.631% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -135964.987% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -7911968.703% |
| Skye Bioscience, Inc. | 11.94 Million USD | -318331.25% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -97776.284% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -526537.859% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -49796898.191% |
| SQZ Biotechnologies Company | 107.18 Million USD | -35372.585% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -2655008.266% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -52541874.71% |
| Mesoblast Limited | 667.9 Million USD | -5592.764% |
| Marizyme, Inc. | 22.01 Million USD | -172608.928% |
| Genus plc | 1.02 Billion USD | -3595.403% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -2799025.117% |
| Pharming Group N.V. | 462.85 Million USD | -8114.685% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -1147556.574% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -7618943.802% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -6064014.832% |
| ContraFect Corporation | 20.67 Million USD | -183767.692% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -9739990.069% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -9948693.36% |
| IMV Inc. | 31.33 Million USD | -121245.052% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -916971.834% |
| MultiCell Technologies, Inc. | 126.22 USD | -30123593624.449% |
| ONE Bio Corp. | 70.08 Million USD | -54150.875% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -4046132.317% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -29486.803% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -8807119.594% |
| Q BioMed Inc. | 3.51 Million USD | -1081447.892% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -107981.526% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -14552271.621% |
| Biomind Labs Inc. | 73.81 Thousand USD | -51506964.576% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | -8419.211% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -2624200.908% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -126576.864% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -1384363.294% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -5530485.35% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -1460489.214% |
| GB Sciences, Inc. | 103.44 Thousand USD | -36756729.913% |
| Alpha Cognition Inc. | 2.45 Million USD | -1550445.027% |
| HST Global, Inc. | 1526.00 USD | -2491611957.602% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -3848409.11% |
| Halberd Corporation | 10.13 Thousand USD | -375303423.828% |
| Enzolytics Inc. | 361.7 Million USD | -10411.834% |
| Agentix Corp. | 261.39 Thousand USD | -14545869.272% |
| Resverlogix Corp. | 8.11 Million USD | -468439.741% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -2024630.015% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | -737.036% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -79607.35% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -5944032.471% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -166902143.093% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -424766.929% |
| AVAX Technologies, Inc. | 7.37 Million USD | -515301.8% |
| Zenith Capital Corp. | 7410.00 USD | -513117308.893% |
| Genscript Biotech Corporation | 3.38 Billion USD | -1022.791% |
| Ember Therapeutics, Inc. | 184.00 USD | -20664130334.239% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -11815093.004% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -14547427.586% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -4097270.471% |
| Kadimastem Ltd | 2.3 Million USD | -1650103.118% |
| Helix BioMedix, Inc. | 3.02 Million USD | -1256789.887% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -72046.639% |
| BioStem Technologies, Inc. | 14.56 Million USD | -261034.891% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -66595339.099% |
| LadRx Corporation | 2.3 Million USD | -1647384.577% |
| Cell Source, Inc. | 195.17 Thousand USD | -19481277.868% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -10752211.116% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -10752211.116% |
| NovAccess Global Inc. | 62.24 Thousand USD | -61081380.528% |
| Affymax, Inc. | 7.44 Million USD | -510742.402% |
| Itoco Inc. | 1.4 Million USD | -2715617.477% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -39748167.245% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -35869711.32% |
| Mobile Lads Corp. | 52.00 USD | -73119230667.308% |
| CytoDyn Inc. | 11.13 Million USD | -341333.19% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -26593918.408% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -212650906.706% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -9863677.041% |
| SYBLEU INC | 330.46 Thousand USD | -11505401.289% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -9286650.59% |
| International Stem Cell Corporation | 5.39 Million USD | -705317.44% |
| Bioxytran, Inc. | 137.63 Thousand USD | -27624538.544% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -253349.079% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -229238.32% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -48129013.923% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -4397148.915% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -505713.489% |
| Neutra Corp. | 2851.00 USD | -1333637220.203% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -117230.124% |
| PureTech Health plc | 693.97 Million USD | -5378.888% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -470988.846% |
| IXICO plc | 15.84 Million USD | -239878.748% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -458992.007% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -36698.808% |
| CSL Limited | 38.02 Billion USD | 0.0% |
| Cellectis S.A. | 333.99 Million USD | -11284.015% |